Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation
This study is to compare 2-year Disease Free Survival Rate (DFSR) in post radical operation IIIA Non-Small Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) 19 or 21 exon mutation treated Erlotinib vs NP chemotherapy as adjuvant therapy.
Non-small Cell Lung Cancer Stage III
DRUG: Erlotinib|DRUG: cis-platinum|DRUG: Vinorelbine
2-year disease free survival rate (DFSR), 2-year disease free survival rate is defined as the estimation percentage of disease free survival patients with study treatment at 2-year., 2 years
disease free survival, Disease free survival is defined as the time from randomization to disease recurrence or death which comes first., 5 years|overall survival (OS), Overall survival is defined as the time from randomization to death., 5 years|Quality of Life, The score of Functional Assessment of Cancer Therapy - Lung (FACT-L) subscale and Lung Cancer Symptom Scale (LCSS), 5 years|Adverse Event (AE), frequency of Adverse Event, 5 years|Serious Adverse Event (SAE), Frequency of Serious Adverse Event (SAE), 5 years
This study is to compare 2-year Disease Free Survival Rate (DFSR) in post radical operation IIIA Non-Small Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) 19 or 21 exon mutation treated Erlotinib vs NP chemotherapy as adjuvant therapy.